Q-omics provides the consensus-scored LASP1 profile across patient tissues and cancer cell-line models. LASP1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LASP1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, LASP1 protein abundance shows 26,176 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, HNSC, and PDAC as cancer lineages where LASP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LASP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LASP1 survival associations across molecular data types. LASP1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LASP1 RNA expression–survival associations across cancer types. High LASP1 expression shows unfavorable associations in MESO, LIHC, ACC and LUAD, but favorable associations in KIRC and STAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LASP1 RNA expression.
This table summarizes LASP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LASP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LASP1 shows higher tumor expression in HNSC, KIRC, KIRP, THCA, LIHC and BLCA. The HNSC box plot shows higher LASP1 RNA expression in tumor versus normal tissue (log2 FC = +1.263, t-test p < 0.001).
This table shows molecular features associated with LASP1 in patient tissues and cancer cell lines. In patient samples, LASP1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, LASP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
